世界の肥大型心筋症（HCM）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3003 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、肥大型心筋症（HCM）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（βアドレナリン遮断薬、カルシウムチャネル遮断薬、抗不整脈薬、抗凝固薬、その他）、用途別市場規模（病院薬局、小売薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・肥大型心筋症（HCM）治療の市場動向 ・企業の競争状況、市場シェア ・肥大型心筋症（HCM）治療の種類別市場規模（βアドレナリン遮断薬、カルシウムチャネル遮断薬、抗不整脈薬、抗凝固薬、その他） ・肥大型心筋症（HCM）治療の用途別市場規模（病院薬局、小売薬局） ・肥大型心筋症（HCM）治療の北米市場規模2016-2027（アメリカ、カナダ） ・肥大型心筋症（HCM）治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・肥大型心筋症（HCM）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・肥大型心筋症（HCM）治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・肥大型心筋症（HCM）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AstraZeneca、Concordia International、Gilead Sciences、Merck、Mylan、Novartis、Pfizer、Sanofi、Teva Pharmaceutical Industries） ・結論

Hypertrophic Cardiomyopathy (HCM) is a condition in which a portion of the heart becomes thickened without an obvious cause. This results in the heart being less able to pump blood effectively. Symptoms vary from none to feeling tired, leg swelling, and shortness of breath. It may also result in chest pain or fainting.

Market Analysis and Insights: Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market
The global Hypertrophic Cardiomyopathy (HCM) Therapeutics market size is projected to reach US$ 1116.5 million by 2026, from US$ 1055.7 million in 2019, at a CAGR of 0.8% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hypertrophic Cardiomyopathy (HCM) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hypertrophic Cardiomyopathy (HCM) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hypertrophic Cardiomyopathy (HCM) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hypertrophic Cardiomyopathy (HCM) Therapeutics market.

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Scope and Market Size
Hypertrophic Cardiomyopathy (HCM) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hypertrophic Cardiomyopathy (HCM) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Beta Adrenergic Blocking Agents
Calcium Channel Blockers
Antiarrhythmic Agents
Anticoagulants
Others

Segment by Application
Hospital Pharmacies
Retail Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AstraZeneca
Concordia International
Gilead Sciences
Merck
Mylan
Novartis
Pfizer
Sanofi
Teva Pharmaceutical Industries

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Beta Adrenergic Blocking Agents
1.2.3 Calcium Channel Blockers
1.2.4 Antiarrhythmic Agents
1.2.5 Anticoagulants
1.2.6 Others
1.3 Market by Application
1.3.1 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Perspective (2016-2027)
2.2 Hypertrophic Cardiomyopathy (HCM) Therapeutics Growth Trends by Regions
2.2.1 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hypertrophic Cardiomyopathy (HCM) Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Hypertrophic Cardiomyopathy (HCM) Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Hypertrophic Cardiomyopathy (HCM) Therapeutics Industry Dynamic
2.3.1 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Trends
2.3.2 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Drivers
2.3.3 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Challenges
2.3.4 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Hypertrophic Cardiomyopathy (HCM) Therapeutics Players by Revenue
3.1.1 Global Top Hypertrophic Cardiomyopathy (HCM) Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue
3.4 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Concentration Ratio
3.4.1 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in 2020
3.5 Hypertrophic Cardiomyopathy (HCM) Therapeutics Key Players Head office and Area Served
3.6 Key Players Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Solution and Service
3.7 Date of Enter into Hypertrophic Cardiomyopathy (HCM) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Hypertrophic Cardiomyopathy (HCM) Therapeutics Breakdown Data by Type
4.1 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Forecasted Market Size by Type (2022-2027)

5 Hypertrophic Cardiomyopathy (HCM) Therapeutics Breakdown Data by Application
5.1 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size (2016-2027)
6.2 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type
6.2.1 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2027)
6.3 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application
6.3.1 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2027)
6.4 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country
6.4.1 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size (2016-2027)
7.2 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type
7.2.1 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2027)
7.3 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application
7.3.1 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2027)
7.4 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country
7.4.1 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size (2016-2027)
9.2 Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type
9.2.1 Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application
9.3.1 Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country
9.4.1 Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Hypertrophic Cardiomyopathy (HCM) Therapeutics Introduction
11.1.4 AstraZeneca Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
11.1.5 AstraZeneca Recent Development
11.2 Concordia International
11.2.1 Concordia International Company Details
11.2.2 Concordia International Business Overview
11.2.3 Concordia International Hypertrophic Cardiomyopathy (HCM) Therapeutics Introduction
11.2.4 Concordia International Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
11.2.5 Concordia International Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Details
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Hypertrophic Cardiomyopathy (HCM) Therapeutics Introduction
11.3.4 Gilead Sciences Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
11.3.5 Gilead Sciences Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Hypertrophic Cardiomyopathy (HCM) Therapeutics Introduction
11.4.4 Merck Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
11.4.5 Merck Recent Development
11.5 Mylan
11.5.1 Mylan Company Details
11.5.2 Mylan Business Overview
11.5.3 Mylan Hypertrophic Cardiomyopathy (HCM) Therapeutics Introduction
11.5.4 Mylan Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
11.5.5 Mylan Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Hypertrophic Cardiomyopathy (HCM) Therapeutics Introduction
11.6.4 Novartis Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
11.6.5 Novartis Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Hypertrophic Cardiomyopathy (HCM) Therapeutics Introduction
11.7.4 Pfizer Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
11.7.5 Pfizer Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Hypertrophic Cardiomyopathy (HCM) Therapeutics Introduction
11.8.4 Sanofi Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
11.8.5 Sanofi Recent Development
11.9 Teva Pharmaceutical Industries
11.9.1 Teva Pharmaceutical Industries Company Details
11.9.2 Teva Pharmaceutical Industries Business Overview
11.9.3 Teva Pharmaceutical Industries Hypertrophic Cardiomyopathy (HCM) Therapeutics Introduction
11.9.4 Teva Pharmaceutical Industries Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
11.9.5 Teva Pharmaceutical Industries Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Beta Adrenergic Blocking Agents
Table 3. Key Players of Calcium Channel Blockers
Table 4. Key Players of Antiarrhythmic Agents
Table 5. Key Players of Anticoagulants
Table 6. Key Players of Others
Table 7. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Regions (2016-2021)
Table 11. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Regions (2022-2027)
Table 13. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Trends
Table 14. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Drivers
Table 15. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Challenges
Table 16. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Restraints
Table 17. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Players (2016-2021)
Table 19. Global Top Hypertrophic Cardiomyopathy (HCM) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics as of 2020)
Table 20. Ranking of Global Top Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Solution and Service
Table 24. Date of Enter into Hypertrophic Cardiomyopathy (HCM) Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share by Type (2016-2021)
Table 28. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share by Application (2016-2021)
Table 32. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 64. AstraZeneca Company Details
Table 65. AstraZeneca Business Overview
Table 66. AstraZeneca Hypertrophic Cardiomyopathy (HCM) Therapeutics Product
Table 67. AstraZeneca Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021) & (US$ Million)
Table 68. AstraZeneca Recent Development
Table 69. Concordia International Company Details
Table 70. Concordia International Business Overview
Table 71. Concordia International Hypertrophic Cardiomyopathy (HCM) Therapeutics Product
Table 72. Concordia International Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021) & (US$ Million)
Table 73. Concordia International Recent Development
Table 74. Gilead Sciences Company Details
Table 75. Gilead Sciences Business Overview
Table 76. Gilead Sciences Hypertrophic Cardiomyopathy (HCM) Therapeutics Product
Table 77. Gilead Sciences Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021) & (US$ Million)
Table 78. Gilead Sciences Recent Development
Table 79. Merck Company Details
Table 80. Merck Business Overview
Table 81. Merck Hypertrophic Cardiomyopathy (HCM) Therapeutics Product
Table 82. Merck Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021) & (US$ Million)
Table 83. Merck Recent Development
Table 84. Mylan Company Details
Table 85. Mylan Business Overview
Table 86. Mylan Hypertrophic Cardiomyopathy (HCM) Therapeutics Product
Table 87. Mylan Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021) & (US$ Million)
Table 88. Mylan Recent Development
Table 89. Novartis Company Details
Table 90. Novartis Business Overview
Table 91. Novartis Hypertrophic Cardiomyopathy (HCM) Therapeutics Product
Table 92. Novartis Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021) & (US$ Million)
Table 93. Novartis Recent Development
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Hypertrophic Cardiomyopathy (HCM) Therapeutics Product
Table 97. Pfizer Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021) & (US$ Million)
Table 98. Pfizer Recent Development
Table 99. Sanofi Company Details
Table 100. Sanofi Business Overview
Table 101. Sanofi Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021) & (US$ Million)
Table 102. Sanofi Recent Development
Table 103. Teva Pharmaceutical Industries Company Details
Table 104. Teva Pharmaceutical Industries Business Overview
Table 105. Teva Pharmaceutical Industries Hypertrophic Cardiomyopathy (HCM) Therapeutics Product
Table 106. Teva Pharmaceutical Industries Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021) & (US$ Million)
Table 107. Teva Pharmaceutical Industries Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Beta Adrenergic Blocking Agents Features
Figure 3. Calcium Channel Blockers Features
Figure 4. Antiarrhythmic Agents Features
Figure 5. Anticoagulants Features
Figure 6. Others Features
Figure 7. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Application: 2020 VS 2027
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Hypertrophic Cardiomyopathy (HCM) Therapeutics Report Years Considered
Figure 11. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Regions: 2020 VS 2027
Figure 14. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Regions (2022-2027)
Figure 15. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Players in 2020
Figure 16. Global Top Hypertrophic Cardiomyopathy (HCM) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hypertrophic Cardiomyopathy (HCM) Therapeutics as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in 2020
Figure 18. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share by Type (2016-2021)
Figure 19. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share by Type (2022-2027)
Figure 20. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Type (2016-2027)
Figure 22. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Application (2016-2027)
Figure 23. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Country (2016-2027)
Figure 24. United States Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Type (2016-2027)
Figure 28. Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Application (2016-2027)
Figure 29. Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Country (2016-2027)
Figure 30. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Region (2016-2027)
Figure 40. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Type (2016-2027)
Figure 48. Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Application (2016-2027)
Figure 49. Latin America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Country (2016-2027)
Figure 50. Mexico Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Share by Country (2016-2027)
Figure 56. Turkey Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. AstraZeneca Revenue Growth Rate in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
Figure 60. Concordia International Revenue Growth Rate in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
Figure 61. Gilead Sciences Revenue Growth Rate in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
Figure 62. Merck Revenue Growth Rate in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
Figure 63. Mylan Revenue Growth Rate in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
Figure 64. Novartis Revenue Growth Rate in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
Figure 65. Pfizer Revenue Growth Rate in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
Figure 66. Sanofi Revenue Growth Rate in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
Figure 67. Teva Pharmaceutical Industries Revenue Growth Rate in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---